Abstract
Background and Aims The progressive nature of Crohn’s disease is highly variable and hard to predict. In addition, symptoms correlate poorly with mucosal inflammation. There is therefore an urgent need to better characterise the heterogeneity of disease trajectories in Crohn’s disease by utilising objective markers of inflammation. We aimed to better understand this heterogeneity by clustering Crohn’s disease patients with similar longitudinal faecal calprotectin profiles.
Methods Latent class mixed models were used to model faecal calprotectin trajectories within five years of diagnosis and to cluster subjects. Information criteria, alluvial plots, and cluster trajectories were used to decide the optimal number of clusters. Chi-squared, Fisher’s exact test, and ANOVA were used to test for associations with variables commonly assessed at diagnosis.
Results Our study cohort comprised of 365 patients with newly diagnosed Crohn’s disease and 2856 faecal calprotectin measurements taken within five years of diagnosis (median 7 per subject). Four distinct clusters were identified by characteristic calprotectin profiles: a cluster with consistently high faecal calprotectin and three clusters characterised by different downward longitudinal trends. Cluster membership was significantly associated with smoking (p = 0.015), upper gastrointestinal involvement (p < 0.001), and early biologic therapy (p < 0.001).
Conclusions Our analysis demonstrates a novel approach to characterising the heterogeneity of Crohn’s disease by using faecal calprotectin. The group profiles do not simply reflect different treatment regimes and do not mirror classical disease progression endpoints. We believe these profiles represent an entirely new way of classifying disease behaviour in Crohn’s disease.
Competing Interest Statement
NC-C: none declared; KM-G: none declared; NP has received consultancy fees from Takeda, speaker fees and/or travel support from Abbvie, Takeda, Norgine; LAAPD has received consultancy fees from Sandoz, speaking fees from Janssen; BG has received consultancy fees from Abbvie ; REM: has received a speaker fee from Illumina, is a scientific advisor to the Epigenetic Clock Development Foundation, and is a scientific consultant to Optima Partners; CWL has received research support from Abbvie and Gilead, consultancy fees from Abbvie, Pfizer, Janssen, Gilead, Celltrion, Pharmacosmos, Takeda, Vifor, Iterative Scopes and Trellus Health; speaker fees and/or travel support from Janssen, Abbvie, Pfizer, Dr Falk, Ferring, Hospira, and Takeda; CAV: none declared.
Funding Statement
This work has been supported by the Medical Research Council & University of Edinburgh Precision Medicine PhD studentship (MR/N013166/1, to NC-C) and the UKRI Future Leaders Fellowship (MR/S034919/1, to CWL. KM-G was supported by an MRC University Unit grant to the MRC Human Genetics Unit.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
As this study was considered a retrospective audit due to all data having been collected as part of routine clinical care, no ethical approval or consent was required as per UK Health Research Authority guidance. Caldicott guardian approval (NHS Lothian) was granted (Project ID: 18002).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† Shared senior authorship
Manuscript has been revised to make clearer the model presented is intended purely as an explanatory model and not to be used for risk predictions in the clinic; Survival analysis followup is now across five years from diagnosis, the same followup period as faecal calprotectin observations (previously survival analysis followup was across all EHR data available).
Data Availability
The data used in this study is not publicly available as it originates from patients who have not given consent for the data to be publicly shared. For access to the data, please contact CWL.
